

Novo Neurologi


This document and presentation contains forward-looking statements, including statements concerning the market positions of our IP, its implementation, and the potential of its products and product outcomes, which are based on information and assumptions available to Novo Neurologi as of the date of this document.

Actual results, performance or outcomes could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document.

Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

# Our view of the Problem

- Patients are taking too many drugs too often
- There are numerous unintended but “acceptable” side effects that are tolerated
- Patients become their disease




Novo Neurologi

At Novo Neurologi we have taken a creative approach to commercialising the research, development and outcomes designed to improve the health and wellbeing of humans with neurodegenerative disorders.

# Our Therapeutic Focus

The implementation of the frameworks for the treatment and management of ...

- Parkinson's Disease
- Obesity / Anorexia
- Psychosis
- Drug Addiction
- Epilepsy
- Alzheimer's
- Heart Disease
- Depression



# What we do that's different

Our IP is based around reformulation and novel drug applications based on:

- Strategic circadian dependent co-administration regimens
- Micro-dosing down to 1/12,000 of the “normal” drug dosage
- Developed new routes and rates of administration
- Strategic co-rerouting of drug compliments
- Reduced number of dosings per unit of time
- Lesser number of interventions (1 per 6 months vs TDS)

# Our IP

- Is based on world-leading technologies with a focus on long term control of a number of neurological disorders based on excellent science.
- Ongoing comprehensive patent protection strategies across all key regions.
- Multiple therapeutic applications each with significant international market opportunities.




# Implementation

- Micro-dose drug delivery
- New routes for drug delivery
- Opportunity for reformulation of existing drugs
  
- Improved quality of life
- Clinicians Patient Management and Assessment System
- Non-Invasive Therapies


# The Market – Parkinson’s Disease

- ~10,000,000 world wide with the disease
- 1.7 Million Life Years lost per annum (DALY)
- Market size – \$2.5b
- 5 Year Forecast – CAGR 5.7%




# The Market – Obesity / Anorexia

- World current market ~\$1.5b
- Forecast 5 year - +\$8.0b




# The Market – Psychosis

- Current Market - +\$11.0b
- Forecast CAGR - 2.5%
- Market challenged by misdiagnosis along with dangerous side effects. Many drugs used to treat other diseases are seen as catalyst for core issues.




# The Market – Drug Addiction

- Current Market - +\$35.0b
- Forecast CAGR - +3.8%
- 1 drug 1 issue 1 market  
Methadone – UK £6bn
- Market challenged by variable efficacy, poor tolerability with “tolerated” dangerous side effects



# Where we are at



# What we are seeking?

The Novo Neurologi's current focus is on securing a partner to advance its treatment for Parkinson's Disease, which is six months away from clinical trials. The partnership have the opportunity to take an application to Phase 1a, allowing the Investment Partner to complete commercialisation across a range of drugs in an application area.

The sorts of partners we are seeking are those with a comprehensive understanding across a range of treatments, including the neurological space. We are not geographic agnostic and we are highly flexible in relation to the types of structural outcomes for the ongoing ownership and use of the IP.

# Who Are We?

## Novo Motologi Group

### **Novo Neurologi**


Focuses on neurodegenerative disorders.

### Novo Motologi

Focuses on cow health and well being in the dairy industry.

### Novo Toxicologi

Focuses on neurotoxicology and environmental toxicology.





# Our Research Partners



The Bronowski Institute of Behavioural Neuroscience

Dr Greg Willis

# Novo Neurologi is about

- Reduction in drug requirements in all areas
- Increasing the efficacy of drugs
- Dramatically reducing the investment in drug development
- Developing less invasive treatment regimes
- Providing patients with fewer side effects and an improved quality of life



Novo Neurologi - Novo Motologi – AusBiotech 2017